Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963785 | 0.95 | TRPM8 (0.49) | PPARAPPARGTRPM8PPARDMAPT | |
| SCHEMBL3960802 | 0.92 | MAPT (0.49) | PPARAPPARGTRPM8PPARDMAPT | |
| SCHEMBL3960804 | 0.91 | MEN1 (0.46) | PPARAPPARGTRPM8MAPTTP53 | |
| SCHEMBL3966524 | 0.91 | PPARA (0.59) | PPARAPPARGTRPM8PPARD | |
| SCHEMBL3963569 | 0.91 | TRPM8 (0.55) | PPARAPPARGTRPM8PPARDFFAR1 | |
| SCHEMBL3963635 | 0.88 | TRPM8 (0.54) | PPARATRPM8MAPTTP53 | |
| SCHEMBL3964001 | 0.88 | TRPM8 (0.45) | PPARAPPARGTRPM8PPARDFFAR1 | |
| SCHEMBL3956888 | 0.87 | TP53 (0.53) | PPARATRPM8MAPTFFAR1TP53 | |
| SCHEMBL3963050 | 0.86 | PPARA (0.57) | PPARAPPARGTRPM8PPARD | |
| SCHEMBL3959919 | 0.85 | PPARA (0.54) | PPARAPPARGTRPM8PPARDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885TRPM8 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.